Finding Balance through Innovation

MONDAY, OCTOBER 3, 2011

2:00 P.M.

Welcome

Delos "Toby" Cosgrove, MD
Chief Executive Officer and President
Cleveland Clinic

Thomas Graham, MD
Chair, Innovations, Cleveland Clinic

2:15 P.M.

Cardiovascular Care's Most Pressing Challenges
Bruce Lytle, MD

Chair, Heart and Vascular Institute, Cleveland Clinic

Perspectives from the Top of Industry

Moderator: Maria Bartiromo, Anchor, CNBC

Leaders of some of the most influential organizations in healthcare provide their unique outlook on the current challenges and strengths of the healthcare industry, the climate for innovation, where we are, and where we are headed.

Ursula Burns, Chief Executive Officer, Xerox
Delos "Toby" Cosgrove, MD
Harry Rein, General Partner, Foundation Medical Partners
John Sheets, PhD, Senior Vice President, Corporate Research, Boston Scientific
Dan Starks, Chief Executive Officer, St. Jude Medical

3:45 P.M.

The 2012 Elections and its Effect on Innovation

Moderator: Paul Begala, Political Analyst and Commentator, CNN and Columnist, Newsweek and The Daily Beast

Rarely has medical innovation played such a central role in US elective politics. This bipartisan panel of top former elected officials and strategists will discuss how healthcare innovation will play out in the 2012 election and beyond.

Ray Gilmartin, Harvard Business School

Ezra Klein, Columnist, The Washington Post
Gail Wilensky, PhD, Senior Fellow, Project HOPE

4:45 P.M.

The Grand Scientific Challenges in Cardiovascular Care

A discussion on the key scientific challenges driving the world of cardiovascular care.

Ferid, Murad, MD, PhD, Nobel Laureate and Professor, George Washington University

5:15 - 6:30 P.M.

Wine Tasting
Welcome Reception

6:30 P.M.

Healthcare as a Pillar of Competitiveness
Mr. Immelt will share how improving healthcare is central to future competitiveness. He will discuss the role of innovation in breaking through the barriers of cost, quality and access and share his thoughts on sustaining healthcare and innovation in meaningful ways. His comments will be followed with a conversation with Maria Bartiromo.

Introduction: Delos "Toby" Cosgrove, MD

Moderator: Maria Bartiromo, Anchor, CNBC

Jeffrey Immelt, Chairman and Chief Executive Officer, General Electric

TUESDAY, OCTOBER 4, 2011

7:00-8:00 A.M.

Procedural Demonstrations

Moderators:

Nicholas Smedira, MD, Interventional Cardiology, Cleveland Clinic

Murat Tuzcu, MD, Vice Chair, Cardiovascular Medicine, Cleveland Clinic

Attendees will see the latest innovations in LVAD Implantation and Transcatheter Aortic Valve Replacements.

Surgeons:

Gonzalo Gonzales-Stawinski, MD, Thoracic and Cardiovascular Surgery, Cleveland Clinic

Samir Kapadia, MD, Interventional Cardiology, Cleveland Clinic

Randall Starling, MD, Thoracic and Cardiovascular Surgery, Cleveland Clinic

Lars Svensson, MD, PhD, Thoracic and Cardiovascular Surgery, Cleveland Clinic

8:00 -9:00 A.M.

The Shifting Cardiovascular Medical Device Environment

Moderator: Steve Sternberg, USA Today

CEOs and executive leaders of the most important organizations in the cardiovascular device community, including the FDA, will discuss the state of device innovation and adoption.

Bernard Lyons, PhD, Chief Executive Officer, Direct Flow Medical

Michael Mussallem, Chief Executive Officer, Edwards Lifesciences

Ferolyn Powell, Divisional Vice President & General Manager, Structural Heart, Abbott Vascular

Murat Tuzcu, MD, Vice Chair, Cardiovascular Medicine, Cleveland Clinic

Bram Zuckerman, MD, Director, Division of Cardiovascular Devices, US, Food and Drug Administration

9:00-10:00 A.M.

The State of Cardiovascular Drug Development

Moderator: Roger Longman, Chief Executive Officer, Real Endpoints

Leaders of the major pharmaceutical companies review the systematic breakthroughs in cardiovascular pharmacology and discuss how careful planning - not serendipity - has helped achieve significant advancements in the current treatment.

Howard Hutchinson, MD, Chief Medical Officer, AstraZeneca

Clive Meanwell, Chief Executive Officer, The Medicines Company

Steven Nissen, MD, Chair, Cardiovascular Medicine, Cleveland Clinic

Michael Rosenblatt, MD, Chief Medical Officer, Merck

John Smith, MD, PhD, Senior Vice President, Clinical Department and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

10:00-10:15 A.M.

Break

10:15-11:15 A.M.

Treating the Heart Failure Patient: New Technology, New Promise

Moderator: Robert Bazell, Chief Science and Health Correspondent, NBC

Heart failure remains the largest single disease in all of healthcare- chief executives and top clinicians examine new breakthrough therapies currently under development.

Gary Burbach, Chief Executive Officer, Thoratec

Eric Fain, MD, President, Cardiac Rhythm Management Division, St. Jude Medical

Douglas Godshall,Chief Executive Officer, Heartware

Gonzalo Gonzalez-Stawinski, MD, Thoracic and Cardiovascular Surgery, Cleveland Clinic

Pat Mackin, Senior Vice President, Cardiac Rhythm Disease Management, Medtronic

Randall Starling, MD, Medical Director, Kaufman Center for Heart Failure, Cleveland Clinic

11:15 A.M. -12:15 P.M.

Peripheral Arterial Disease: New Innovations to Treat  a Growing Cohort

Moderator: Michelle Cortez, Bloomberg

Peripheral Artrerial Disease is considered a largely unaddressed disease market mostly due to the special challenges of fighting cardiovascular disease in the periphery. Top leaders in the field discusses the prospect for new breakthroughs.

Dan Clair, MD, Chair, Vascular Surgery, Cleveland Clinic

Robert "Chip" Hance, President, Abbott Vascular

Tim Ring, Chief Executive Officer, CR Bard

Campbell Rogers, MD,Chief Scientific Officer and Global Head, Research and Development, Cordis Corporation

John Simpson, MD, Chief Executive Officer, Avinger

12:15-1:35 P.M.

Partnering for Biomedical Innovation: Starting the Dialogue

Ian Read, Chief Executive Officer, Pfizer

Biomedical innovation has improved human life and created wealth in our society, but there are challenges to ongoing innovation in medicine. The talk will examine these challenges and create an opportunity to start a dialogue among healthcare providers across the industry to evaluate how, together, we can earn the respect of society, alter policies to support ongoing medical innovation and collaborate to create more efficient ways to treat patients.

1:40-2:40 P.M.

Cardiovascular Investing: Compelling Opportunities or Aging Grand Dame?

Moderator: Roger Longman

Do investment opportunities in cardiovascular technology still provide sufficient return potential after more than half a century of active venture investing?

Reinhard Ambros, PhD, Executive Director and Head, Novartis Venture Funds

Mike Buck, Divisional Vice President, Abbott Ventures

Marc Gillinov, MD, Thoracic and Cardiovascular Surgery, Cleveland Clinic

John Maroney, General Partner, Delphi Ventures

Jason Mills, Managing Director, Equity Research, Medical Devices, Canaccord Genuity

Antoine Papiernik, Managing Partner, Sofinnova

2:40 - 3:45 P.M.

Ensuring the Innovation Balance: White Oak vs. Brussels

Moderator: Robert Bazell

The chief leaders of the three principle industry associations will engage top regulatory leaders to discuss the state of regulatory approval in the US and perceptions about greater flexibility in overseas markets.

John Castellani, Chief Executive Officer, PhRMA
Roy Greenberg, MD, Vascular Surgery, Cleveland Clinic
James Greenwood, Chief Executive Officer, BIO
Stephen Ubl, President, AdvaMed

3:45-4:15 P.M.

Revitalizing a Market-Leading Cardiac Franchise in a Time of Economic Challenge

Omar Ishrak, Chief Executive Officer, Medtronic

At a time when economic challenges and healthcare reform are impacting patients, payers, healthcare providers and device manufacturers alike, it is critical for stakeholders across the treatment continuum to work together to find solutions that improve efficiencies and reduce the cost of healthcare - all while delivering better therapeutic options to patients and their physicians. Mr. Ishrak will explore the significant unmet clinical needs that patients and their physicians face, and will make the case for why technology combined with an increased focus on economic value can revitalize the cardiac franchise.

4:15-4:30 P.M.

Break

4:30-5:15 P.M.

Beyond Jeopardy! The Implications of IBM's Watson

Watson was built to rival human's ability to answer questions posed in natural language with speed, accuracy and confidence. The system passed its first test on Jeopardy!, beating the show's two greatest champions, but the real test will be in applying the underlying data management and analytics technology across industries like healthcare. Join us to see two of Cleveland Clinic's top cardiovascular clinicians challenge Watson and learn about future implications.

Introduction: David Ferrucci, PhD, Principal Investigator, DeepQA/Watson Project, IBM Research

Challenge Host: David Shepler, Jeopardy Challenge Program Manager, IBM

Marc Gillinov, MD
Steve Nissen, MD
Watson, IBM

5:15-6:15 P.M.

Breakout Sessions

Concurrent sessions will be held to allow a deep dive into cutting edge cardiovascular issues.

- Cardiovascular's Special Regulatory Challenges

Moderator: Howard Holstein, Partner, Hogan Lovells US LLP

A top regulatory consultant will moderate a focused discussion between venture capitalists, a top FDA leader and the head of Cleveland Clinic's clinical trial center on pending regulatory changes and their impact on the cardiovascular regulatory landscape.

Jan Garfinkle, Managing Partner, Arboretum Ventures
Michael Lincoff, MD, Vice Chairman, Cardiovascular Medicine, Cleveland Clinic
Rebecca Robertson, Managing Director, Versant Ventures

William Maisel, MD, Deputy Center Director, Sciences and CDRH Chief Scientist, U.S. Food and Drug Administration

- Regenerative Medicine: Is the Dream Becoming a Reality?

Moderator: Stephen Ellis, MD, Invasive / Interventional Cardiology, Cleveland Clinic

Top Executives of leading edge companies give their unique and upbeat perspectives on how regenerative medicine to treat the cardiovascular disease is a short step away from reality.

Rahul Aras, PhD, Chief Executive Officer, Juventas Therapeutics

Andrea Hunt, MD, Vice President Regenerative Medicine, Baxter Healthcare

Randall Mills, PhD, Chief Executive Officer, Osiris Therapeutics

Gil Van Bokkelen, PhD, Chief Executive Officer, Athersys

- Watson in Everyday Clinical Decision Making

Moderator: Roger Longman

The specifics of how systems like Watson will be put into daily use will be examined by IBM team leaders and two highly IT savvy Cleveland Clinic clinicians.

Basit Chaudhry, MD, PhD, Senior Researcher, Clinical Transformation, Healthcare Analytics, IBM Research

David Ferrucci, PhD
Doug Johnston, MD, Staff Cardiac Surgeon, Cleveland Clinic
William Morris, MD, Associate Staff Hospital Medicine, Cleveland Clinic

- Reimbursement: Innovation's Inner Self

Moderator: Carol Harding, Senior Director, Supply Chain Innovations, Cleveland Clinic

Reimbursement considerations are now core to the devlopment of any new product innovation. This session will examine reimbursement of new cardiovascular technologies from the patient, provider, company and government perspective.

Moderator: Carol Harding, Senior Director Supply Chain Innovations, Cleveland Clinic

Bonnie Handke, RN, Senior Director Reimbursement, Medtronic
Sean Lyden, MD, Vascular Surgery, Cleveland Clinic
Gwen Mayes, Executive Vice President, National Patient Advocate Foundation

- Tour of Cleveland Clinic's Global Cardiovascular Innovation Center (GCIC)

GCIC Provides a state-of-the-art home for medical technology companies in all fields. Designed, built and equipped as one of the fist cardiovascular healthcare focused incubators in the U.S., GCIC delivers 50,000 square feet of prime, brand new space.

6:30-9:00 P.M.

Sunset Dinner Gala & Fireworks Display on the Lake Erie Shore

The Shorby Club

WEDNESDAY, OCTOBER 5, 2011

7:30-8:30 A.M.

Procedural Demonstrations

Moderators:

Bruce Lindsay, MD, Chair, Electrophysiology, Cleveland Clinic

Matthew Eagleton, MD, Vascular Surgery, Cleveland Clinic

Attendees will see the latest innovations in Electrophysiology and Peripheral Arteral Disease Treatments.

Surgeons:

Daniel Clair, MD
Mohamed Kanj, MD, Electophysiology, Cleveland Clinic
Sean Lyden, MD
Walid Saliba, MD, Electrophysiology, Cleveland Clinic
Sunita Srivastava, MD, Vascular Surgery, Cleveland Clinic
Oussama Wazni, MD, Electophysiology, Cleveland Clinic

8:30-9:10 A.M.

The Case for Smarter Medicine

David Snow, Chief Executive Officer, Medco

The prosepects for genuine, sustainable healthcare reform will hinge upon the extent to which innovation, including health information technology, is embraced and implemented system-wide. Mr. Snow will make the case that a truly "wired" healthcare system-the sort already established in the world of advanced pharmacy - has the potential to address issues of medication non-compliance, patient safety and significant imissions in care, leading the way from the current approach of "shotgun medicine" to a new world of precision medicine that can form the foundation for sustainable healthcare reform.

9:10-10:10 A.M.

Breakthroughs in Cardiovascular Imaging: Powerful New Insights; Strong Cost Pressures

Moderator: Michelle Cortez

Clinicians walk a fine line between reliance on ever-improving imaging technology and the cost of acquiring the added information. Join the debate with clinicians and industry executives as they calibrate these trade-offs and the future of cardiovascular imaging.

Rory Hachamovitch,MD, Cardiovascular Imaging, Cleveland Clinic
Douglas Hansell, MD,Chief Medical Officer, Americas, GE Healthcare

Scott Huennekens, Chief Executive Officer, Volcano

Tom Marwick, MD, PhD, Cardiovascular Imaging, Cleveland Clinic
Bert van Meurs, General Manager, Interventional X-Ray, Philips Healthcare

10:10-10:30 A.M.

10:30-11:30 A.M.

Investing in Healthcare IT: The Hottest Market in the Industry

Moderator: Vi Schaffer, Research Vice President, Healthcare Providers, Gartner, Inc.

IT is the hottest market in healthcare. Join these leading experts to discuss investment perspectives and hot new cardiovascular related IT technologies.

Pat Fortune, PhD, Partner, Millennia Partners
Martin Harris, MD, Chief Information Officer, Cleveland Clinic
Mark Kvamme, Chief Investment Officer, JobsOhio
Stephen McHale, Chief Executive Officer, Exporys
John Reardon, Managing Partner, Trident Capital

11:30 -12:30 P.M.

Top 10 Medical Innovations for 2012

Moderator: Michael Roizen, MD, Chief Wellness Officer, Cleveland Clinic

Cleveland Clinic's Top 10 list of breakthrough technologies for the coming year has become an international sensation. Join us again as Dr. Mike Roizen and a panel of ten of the Clinic's physician leaders roll out these much anticipated selections.

12:30-2:00 P.M.

A Patient's Perspective on Cardiovascular Innovation

Moderator: Bob Woodruff, ABC News Anchor

At its most fundamental level, all innovation is about the patient. Please join us for a powerful exchange with one of the nation's best known heart failure patients. The session will include on of the Clinic's leading cardiac surgeons and will be moderated by a top journalist - himself a grateful Cleveland Clinic patient.

Dick Cheney, Former US Vice President

Medicare's Innovation Agenga: What's possible, what's likely and what will it mean to me?

One of the most significant actions taken during this period of healthcare reform was the establishment of the Center for Medicaid and Medicare Innovation at CMS. The leader of the center will discuss his perspectives on healthcare innovation and the role of the world's largest payor.

Richard Gilfillan, MD, Acting Director, Center for Medicaid and Medicare Innovation

2:00 - 2:15 P.M.

Wrap-Up and Adjournment
Joseph Hahn, MD, Chief of Staff, Cleveland Clinic